Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Immvira Bioscience Files for Hong Kong IPO to Advance Novel Oncolytic Immunotherapy and Engineered Exosome Pipeline

Fineline Cube Jul 17, 2026
Company Deals

Eli Lilly to Acquire AtaiBeckley for $3.8 Billion, Accelerating Psychedelic Therapeutics Development for Treatment-Resistant Depression

Fineline Cube Jul 17, 2026
Company Deals

Jasper Therapeutics Completes Acquisition of Kira Pharmaceuticals in All-Stock Transaction, Secures $132M Private Placement for Complement Therapies Pipeline

Fineline Cube Jul 17, 2026
Company Deals

China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline

Fineline Cube Jul 16, 2026
Company Deals

Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset

Fineline Cube Jul 16, 2026
Policy / Regulatory

China’s CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs

Fineline Cube Jul 16, 2026
Company Drug

CSPC Pharmaceutical Launches Phase III Trial of B7-H3-Targeting ADC SYS 6043 for Platinum-Resistant Ovarian Cancer

Fineline Cube Jul 17, 2026
Company Drug

CSPC Pharmaceutical Launches Phase II Trial of Albumin-Bound Sirolimus for Rare Vascular Tumor Epithelioid Hemangioendothelioma

Fineline Cube Jul 17, 2026
Company Deals

CanSino Biologics Partners with Saudi SPIMACO to Boost Meningococcal Vaccine Access

Fineline Cube Mar 26, 2025

China-based CanSino Biologics Inc. (HKG: 6185) has entered into a collaboration agreement with Saudi pharmaceutical...

Company

Everest Medicines Reports Surge in Revenue, Advances Core Products and R&D Pipeline

Fineline Cube Mar 26, 2025

China-based Everest Medicines (HKG: 1952) has announced its 2024 financial results, marking a significant milestone...

Company Deals

Jiangsu Hengrui Pharmaceuticals Inks Global License Deal with Merck for HRS-5346

Fineline Cube Mar 26, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced a license agreement with US-based giant Merck...

Company Drug

Sichuan Kelun-Biotech Gains NMPA Approval for SKB107 Bone Metastasis Trial

Fineline Cube Mar 26, 2025

China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced receiving approval from the National...

Company Drug

Abbisko Therapeutics Receives NMPA Approval for ACH Drug ABSK061

Fineline Cube Mar 26, 2025

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced receiving clinical trial approval from...

Company Deals

Fapon Biotech Partners with Sansure to Develop Next-Generation Diagnostic Solutions

Fineline Cube Mar 26, 2025

China-based biotech Fapon Biotech Inc. has formed a strategic partnership with molecular diagnostics specialist Sansure...

Company Drug

AstraZeneca Officially Launches Fasenra for Severe Eosinophilic Asthma in China

Fineline Cube Mar 25, 2025

UK-based pharmaceutical giant AstraZeneca Inc. (NASDAQ: AZN) has announced the official market launch of its...

Company Deals Drug

United Laboratories Inks Global Licensing Deal with Novo Nordisk for Obesity Drug

Fineline Cube Mar 25, 2025

Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) has entered into a licensing agreement...

Company Deals

Fapon Biotech Partners with Tencent Healthcare to Boost IVD and Medical Device Fields

Fineline Cube Mar 25, 2025

China-based biotech Fapon Biotech Inc. has formed a strategic partnership with Tencent Healthcare, the healthcare...

Company Drug

Joint Biosciences’ OVV-01 Receives FDA Fast Track Designation for Soft Tissue Sarcoma Trial

Fineline Cube Mar 25, 2025

Shanghai-based Joint Biosciences Ltd., a developer of tumor combined immunotherapies, has announced receiving fast track...

Company Drug

Sino Biopharmaceutical’s Culmerciclib Shows Positive Results in Phase III Breast Cancer Trial

Fineline Cube Mar 25, 2025

China-based Sino Biopharmaceutical Ltd (HKG: 1177) has revealed positive results from the Phase III TQB3616-III-02...

Company Drug

Humanwell Healthcare Receives NMPA Approval for Caplyta Generic in Schizophrenia Trial

Fineline Cube Mar 25, 2025

China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) has announced receiving clinical trial approval from...

Company

Clover Biopharmaceuticals Receives Termination Notice from GAVI for COVID-19 Vaccine Agreement

Fineline Cube Mar 25, 2025

China-based Clover Biopharmaceuticals Ltd., (HKG: 2197) announced receiving a one-month prior written notice dated March...

Company

Simcere Pharmaceutical Group Reports Steady Revenue Amid R&D Investment Shift

Fineline Cube Mar 25, 2025

China-based Simcere Pharmaceutical Group (HKG: 2096) has released its 2024 financial performance report, recording RMB...

Company

Henlius Biotech Reports 6.1% Revenue Growth with Strong Oncology Product Sales

Fineline Cube Mar 25, 2025

Shanghai Henlius Biotech Inc. (HKG: 2696) has published its 2024 financial results, recording revenues of...

Company

Sichuan Kelun-Biotech Reports 25.5% Revenue Growth with Key Drug Approvals

Fineline Cube Mar 25, 2025

China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has released its 2024 financial report, recording...

Drug Medical Device Policy / Regulatory

China’s NHSA Releases 2024 Healthcare Security Bulletin Highlighting Insurance Coverage and Reimbursement

Fineline Cube Mar 25, 2025

China’s National Healthcare Security Administration (NHSA) has released its 2024 “Healthcare Security Development Statistical Bulletin.”...

Company Medical Device

Jenscare Scientific’s Ken Valve Receives NMPA Marketing Approval

Fineline Cube Mar 25, 2025

Jenscare Scientific Co., Ltd (HKG: 9877), a Ningbo-based structural heart disease device maker, has announced...

Company Drug

SineuGene Therapeutics’ SNUG01 Receives FDA Clearance for ALS Clinical Study

Fineline Cube Mar 25, 2025

Beijing-based SineuGene Therapeutics, a developer of gene therapies for brain disorders, announced last week that...

Company Drug

GSK’s Nucala Accepted for EMA Review for COPD Treatment

Fineline Cube Mar 25, 2025

UK-based GSK plc’s (LON: GSK, NYSE: GSK) application for expanding the use of its anti-interleukin-15...

Posts pagination

1 … 220 221 222 … 696

Recent updates

  • CSPC Pharmaceutical Launches Phase III Trial of B7-H3-Targeting ADC SYS 6043 for Platinum-Resistant Ovarian Cancer
  • CSPC Pharmaceutical Launches Phase II Trial of Albumin-Bound Sirolimus for Rare Vascular Tumor Epithelioid Hemangioendothelioma
  • Immvira Bioscience Files for Hong Kong IPO to Advance Novel Oncolytic Immunotherapy and Engineered Exosome Pipeline
  • Abbott Reports Strong Q2 2026 Results with 12.2% Revenue Growth Driven by Diagnostics Surge and Medical Device Innovation
  • Hengrui’s HRS9531 Dual GIPR/GLP-1R Agonist Advances to Phase III for Obesity with Knee Osteoarthritis, Expanding Metabolic Disease Portfolio
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

CSPC Pharmaceutical Launches Phase III Trial of B7-H3-Targeting ADC SYS 6043 for Platinum-Resistant Ovarian Cancer

Company Drug

CSPC Pharmaceutical Launches Phase II Trial of Albumin-Bound Sirolimus for Rare Vascular Tumor Epithelioid Hemangioendothelioma

Company Deals

Immvira Bioscience Files for Hong Kong IPO to Advance Novel Oncolytic Immunotherapy and Engineered Exosome Pipeline

Company

Abbott Reports Strong Q2 2026 Results with 12.2% Revenue Growth Driven by Diagnostics Surge and Medical Device Innovation

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.